Intensive care medicine

Primary prevention

Sudden cardiac arrest

Secondary prevention

Clinical trial

Cardiology

Cardiac resynchronization therapy

Defibrillation

Heart failure

Ventricular tachycardia

Internal medicine

Clinical endpoint

Implantable cardioverter-defibrillator

Sudden cardiac death

Medicine

Ejection fraction

Disease

EP Europace

AimsThis study aims to demonstrate that primary prevention (PP) patients with one or more additional risk factors are at a similar risk of life-threatening ventricular arrhythmias when compared with secondary prevention (SP) patients, and would receive similar benefit from an implantable cardioverter defibrillator (ICD), or cardiac resynchronization therapy-defibrillator (CRT-D) implant. The study evaluates the benefits of therapy for high-risk patients in countries where defibrillation therapy for PP of SCA is underutilized.

Improve the prevention of sudden cardiac arrest in emerging countries: the Improve SCA clinical study design